Cartherics to present and exhibit at Emergence 2024

Cartherics is pleased to announce that it will be attending Emergence 2024 – The Era of Abundance investment conference at the Hilton Sydney next week.

The company’s CEO, Prof. Alan Trounson AO, will be presenting at 11:14 am on Wednesday 28th February. His presentation will discuss:

  • Cartherics’ breakthrough approach to treating solid tumours.
  • How CTH-401, the company’s lead ‘off the shelf’ natural killer (NK) product, destroys ovarian cancer in mouse models and shows sustained efficacy.
  • Clinical trials for CTH-401 in ovarian cancer planned for 2025.
  • Cartherics’ proprietary scalable manufacturing process.
  • The investment opportunity and avenues for shareholder liquidity.

Cartherics is developing ‘off the shelf’ (allogeneic) immune therapies that are ready for on-demand use and can be manufactured at a fraction of the cost of autologous (patient-derived) CAR-T therapies. The company has just completed a successful pre-IND meeting with the FDA on CTH-401 and has received clear advice on what is needed in the next 12 months to be ready to submit an IND for CTH-401. This will allow the company to begin clinical trials in Australia in 2025 and will represent a major value-creating milestone for the company.

“Cartherics is really making major changes to cancer therapy with ovarian cancer our initial target. We have a stem cell-based therapy that allows us to gene edit, deep sequence for any errors, and manufacture immune killer cells from a single stem cell. This is more like a drug therapy than a cell therapy. We are looking forward to taking it to the clinic and seeing the potential benefits to patients with ovarian cancer,” said Prof. Trounson.

Cartherics will also be exhibiting at the Emergence 2024 investment conference, providing an opportunity to meet our team and access additional company information and resources.

Please visit Cartherics’ deal room for further information:

Access complimentary ticket here: